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ster method. Comprehensive transthoracic echocardiography was performed to
evaluate LV ejection fraction (EF), Sa velocity, global longitudinal strain
(GLS), E and Ea velocities and E/Ea ratio. Demographic and clinical data
were similar between the 3 groups. However, HF group were significantly
older than control or CAD groups (65±7 vs. 54±12 or 56±7yrs, p<0.01). Com-
pared to control subjects, patients with CAD or HF had lower DLco and Dm
(33±6 vs. 25±6 vs. 20.5±6, p<0.01; 55±17 vs. 37±10 vs. 30±11ml.min
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.mmHg
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,
p<0.01). In the whole cohort, DLco was correlated with systolic and diastolic
parameters (LVEF: r=0.47, p=0.001; GLS: r=0.35, p=0.02; Sa: r=0.49,
p=0.0007; E/Ea: r=-0.30, p=0.05; Ea: r=0.51, p=0.0006). Similar results were
found with Dm (LVEF: r=0.44, p=0.004; GLS: r=0.33, p=0.03; Sa: r=0.47,
p=0.001 and E/Ea: r=-0.36, p=0.02; Ea: r=0.49, p=0.0009). On multivariate
analysis, after adjustment for age, sex and BMI, independent predictors of
DLco as well as Dm were Ea (r
 
2
 
=0.27, p=0.0006; r
 
2
 
=0.25, p=0.001) and
LVEF<50% (r
 
2
 
=0.08, p=0.03; r
 
2
 
=0.07, p=0.03).
 
Conclusion:
 
 Reduced diffusing lung capacity is related to both LV dias-
tolic and systolic dysfunctions. Ea-wave velocity is the strongest determinant
of this alteration, emphasizing the crucial role of LV relaxation. These find-
ings could explain diffusing lung abnormalities observed in patients with pre-
served LV systolic function.
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Cardiac resynchronization therapy (CRT) is an effective treatment of
advanced heart failure (HF). Recent studies showed a positive effect of CRT
on HF symptoms, left ventricular ejection function (EF,%), reduction of hos-
pitalizations and survival. However, most studies evaluated clinical and
echocardiographic response to CRT after a limited follow-up (ranging from 6
to 12 months).
Thus we evaluated clinical and functional response to CRT in HF patients
(pts) after a longer follow-up period (up to 3 years, ys).
We enrolled 75 HF outpts with CRT indication [30% females, mean age
67.9±12.6 ys, mean NYHA class 2.8±0.7, mean EF 25.7±8.1, HF aetiology:
44% coronary artery disease (CAD), 43% dilated cardiomyopathy (DCM), 6%
hypertensive cardiomyopathy (HT), 7% valvular disease (V)]. All were evalu-
ated by means of ECG, echocardiography, NYHA functional class before CRT
device implant and re-evaluated after 1 (95% of pts), 2 (80% of pts), and 3
(45% of pts) ys.
After 1 y, NYHA significantly improved (from 2.8±0.7 to 2.3±0.6,
p<0.0001), as well as EF (from 25.7±8.1 to 30.1±9.0, p=0.005). This improve-
ment was maintained after 2 ys (NYHA 2.3±0.6, EF 31.8±9.4) and 3 ys
(NYHA 2.2±0.6, EF 33.4±10.2). Overall, we registered 8 deaths, of which 2
(2.7%) after 1 y, 3 (4%) after 2 ys and 3 (4%) after 3 ys. Dividing pts on the
basis of HF aetiology, after 1 y all pts presented a significant improvement,
while further on DCM pts showed a steady increase of EF (basal 22.9±7.8,
after 1 y 28.8±9.5, after 2 ys 31.3±11.1 and after 3 ys 35.4±13.3), while CAD
pts showed stabilization of EF on the first y values (basal 26.3±7.3, after 1 y
29.5±7.4, after 2 ys 29.7±6.3 and after 3 ys 29.9±5.2). Echocardiographic
response to CRT in terms of EF is clearly evident after 1 y and remains
improved after 2 and also 3 ys, with a not significant trend to further improve
in DCM. All pts significantly improved NYHA within the first y. Benefit
deriving from CRT is maintained during long term follow-up.
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Background:
 
 Arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C) is an inherited cardiac disease, usually an autosomal dominant dis-
order, that may lead to sudden death, particularly in young people and athletes.
Five desmosomal genes have been recently implicated in ARVD/C: JUP, DSP,
PKP2, DSG2 and DSC2. We performed a systematic screening of these genes
in a large population to address the potential clinical impact of genotyping.
 
Methods and results: 
 
Direct sequencing of the 5 predefined genes was per-
formed in 135 unrelated patients with ARVD/C meeting the international Task
Force criteria. We identified 66 disease-causing mutations in 61 patients (45%).
Distribution of genes was 31% (41/135) for PKP2, 10% (14/135) for DSG2,
4% (6/135) for DSP, 1% (2/135) for DSC2 and 0% for JUP. The identification
rate was not related to age of patients nor familial context. In 48% (32/66) a
mutation was identified in a single family or individual (private mutation). In
addition, a genetic variant of unknown significance was identified in additional
10 patients (7%). Finally, complex genetic status with double mutations was
identified in 4% of patients and multiple mutations tend to be associated with
a more severe phenotype (namely more frequent cardiac arrest).
 
Conclusions:
 
 We performed the most comprehensive screening of desmo-
somal genes in the largest population of ARVD/C patients reported until now.
A molecular diagnosis strategy can be deduced, requiring however exhaustive
genetic screening of four desmosomal genes, with the possible identification
of genetic variants of unknown significance. The relatively high success rate
of genotyping in ARVD/C suggests the possible use of genetic testing as a
diagnostic tool, with potential important impact for early diagnosis in border-
line patients and relatives.
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Aims: Dilated Cardiomyopathy (DCM) is familial in about 30% of cases,
and mutations have been identified in several genes. However, in a majority
of familial cases the responsible genes are still to be discovered. The ANKRD1
gene is overexpressed in heart failure in human and animal models. The
encoded protein CARP interacts with partners such as Myopalladin or Titin,
previously shown to be involved in DCM. We hypothesised that mutations in
ANKRD1 could be responsible for DCM.
Methods and Results: We sequenced the coding region of ANKRD1 from
231 independent DCM cases. We identified 5 missense mutations (3 sporadic
and 2 familial) absent from 400 controls and affecting highly conserved resi-
dues. Expression of the mutant CARP proteins after transfection in rat neonate
cardiomyocytes indicated that most of them led to both significant less
repressor activity measured in a reporter gene assay and greater phenylephrin
induced hypertrophy suggesting altered function of CARP mutant proteins.
Conclusion: Based on genetic and functional analysis of CARP mutations,
we have identified ANKRD1 as a new gene associated with DCM, accounting
for about 2% of cases.
